Clinical Trial Record

Return to Clinical Trials

Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs


2025-08-31


2026-06-30


2027-07-31


600

Study Overview

Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs). The main questions it aims to answer are: Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions. Participants will: Provide retrospective clinical, pathological, and metabolic data from hospital records. Have survival and recurrence outcomes assessed through follow-up data review.

N/A

  • Pancreatic Neuroendocine Neoplasms (pNETs)
    • KYLL-2025-07-004

    Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates Results Reporting Dates Study Record Updates

    2025-08-14  

    N/A  

    2025-08-21  

    2025-08-21  

    N/A  

    2025-08-22  

    2025-08-22  

    N/A  

    2025-08  

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    Design Details

    Primary Purpose:
    N/A


    Allocation:
    N/A


    Interventional Model:
    N/A


    Masking:
    N/A


    Arms and Interventions

    Participant Group/ArmIntervention/Treatment
    : Early-onset pancreatic neuroendocrine tumors group

    This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.

    : Late-onset pancreatic neuroendocrine tumors group

    This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.

    Primary Outcome MeasuresMeasure DescriptionTime Frame
    Overall SurvivalFrom date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years
    Secondary Outcome MeasuresMeasure DescriptionTime Frame
    Disease-specific survivalFrom date of diagnosis until death due to PanNETs, up to 12 years
    Progression-free survivalFrom date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.
    Disease-free survivalFrom date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.

    Contacts and Locations

    This section provides the contact details for those conducting the study, and information on where this study is being conducted.

    Study Contact

    Name: Hanxiang Zhan, MD. PhD.

    Phone Number: +86 18560085156

    Email: zhanhanxiang@hotmail.com

    Study Contact Backup

    Name: Changhao Gao, MMed

    Phone Number:

    Email: gaochanghao44@gmail.com

    Participation Criteria

    Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

    Ages Eligible for Study:
    ALL

    Sexes Eligible for Study:
    18 Years

    Accepts Healthy Volunteers:

      Inclusion Criteria:

    • 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

    • Exclusion Criteria:

    • Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

    Collaborators and Investigators

    This is where you will find people and organizations involved with this study.

    • China-Japan Friendship Hospital
    • The Affiliated Hospital of Qingdao University
    • Qianfoshan Hospital

    • : ,

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available